David Sinclair· PhD
Epigenetic reprogramming in vivo is now shown to work across systems, from liver to eye, and likely many more
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Epigenetic reprogramming in vivo is now shown to work across systems, from liver to eye, and likely many more
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Next up: epigenetic rejuvenation trials in humans [@lifebiosciences: Today our CEO Jerry McLaughlin presented at the 5th Annual Age-Related Disease Therapeutics Summit in San Francisco on the implications of #partialepigeneticreprogramming, CMA and our recent data on restoring visual function in non-human primates here: https://t.co/JkrEkPCOzH https://t.co/rVPoiPD73O]
In vivo epigenetic reprogramming has Yuge potential.